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Thromboembolic Complications After
Surgical Correction of Mitral Regurgitation
Incidence, Predictors, and Clinical Implications
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William K. Freeman, MD, Rakesh Suri, MD, Hector Michelena, MD, Robert Brown, MD,
Thoralf M. Sundt, MD, FACC, Maurice Enriquez-Sarano, MD, FACC
Rochester, Minnesota
Objectives We sought to define thromboembolic risk after surgery for mitral regurgitation (MR), particularly ischemic stroke
(IS) compared with the general population.
Background Guidelines recommend surgery in asymptomatic patients with MR, but IS risks are unknown.
Methods In 1,344 patients (age 65  12 years) consecutively operated for MR (procedures: 897 mitral valve repair
[MRep] and 447 valve replacement: 231 mechanical mitral valve replacement [MVRm], 216 biological mitral
valve replacement [MVRb]), thromboembolic complications, particularly IS (diagnosed by neurologists), during
follow-up were assessed early (30 days), midterm (30 to 180 days), and long-term (180 days).
Results Ischemic stroke occurred in 130 patients: 1.9  0.4% and 2.7  0.5% at 30 days and 180 days, respectively,
and 8.1  0.8% at 5 years. We found that IS rates were lowest after MRep versus MVRb and MVRm (6.1 
0.9% vs. 8  2.1%, and 16.1  2.7% at 5 years, respectively, p  0.001). Comparison with population-expected
IS showed high risk at 30 days (risk ratio 41, 95% confidence interval 26 to 60, p  0.001 but p  0.10 be-
tween procedures) and moderate risk at 30 days (risk ratio 1.7 overall; 1.3 for MRep; 0.98 for MVRb; 4.8 for
MVRm). Beyond 180 days, IS risk declined further and was similar to the population for MRep (relative risk 1.2)
and for MVRb (relative risk 0.9). Bleeding risk 30 days was lowest in MRep versus MVRb and MVRm (10-year
risk 7  1%, 14  4%, and 16  3%, respectively).
Conclusions Thromboembolic complications after MR surgery are a reason for both concern and encouragement. The risk of
IS is notable early, irrespective of procedure, but in the long term it is not greater than in the population after
MRep and MVRb. Preference for MRep should be emphasized, and trials aiming at preventing IS should be con-
ducted to reduce thromboembolic and hemorrhagic risk after surgery for MR. (J Am Coll Cardiol 2008;51:
1203–11) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.058(
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ehromboembolic events (TEs) are serious complications of
ardiac surgery (1). Most TEs are cerebrovascular (2), with
he most serious, ischemic stroke (IS), resulting in poor
uality of life and excess mortality (1,3–5). The incidence of
S early after cardiac surgery was reported mostly after
See page 1212
oronary artery bypass grafting (CABG) surgery between
% and 8% (1,4–7), but is less known after valve surgery
rom the Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic
ollege of Medicine, Rochester, Minnesota. Dr. Russo was supported by a grant from
he “Luisa Fanti Melloni” foundation from Italy.s
Manuscript received May 1, 2007; revised manuscript received September 24, 2007,
ccepted October 1, 2007.8,9), particularly for mitral regurgitation (MR) (10,11). A
E that occurs after MR surgery is important because
) MR is frequent with aging (12); 2) mitral valve repair
MRep) is preferred for surgical treatment of MR so that
revious data following valve replacement may not be
elevant (13,14); and 3) surgery has been advocated for
symptomatic patients (15), in whom any complication
epresents serious concern. It is thus unclear whether TE
isk is high in any surgery (14) or negligible with MRep
16), making anticoagulation unnecessary, or whether sur-
ery multiplies spontaneous risk of stroke (17) in elderly
atients with MR, a fact that may affect the new liberal
ndications for surgery in such patients. Resolving this
uestion is difficult because with decreased rheumatic dis-
ase, older patients with MR (12) who are referred to
urgery incur spontaneously a greater risk of stroke. There-
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Stroke After Mitral Surgery March 25, 2008:1203–11fore, it is essential to assess abso-
lute TE risk but also to compare
not only observed risk with that
expected in the general popula-
tion (18), but also early and late
post-operative TE risk associated
with MRep and mitral valve re-
placement (MVR). These com-
parisons will determine whether
the survival advantage associated
with MRep (19,20) is additive to
lower embolic rates throughout
follow-up. Thus, we examined
the TE risk associated with var-
ious modalities of surgical cor-
rection of MR, particularly com-
paring IS risk to that expected in
the population.
ethods
he present study was based on the consecutive experience
f our institution (Mayo Clinic, Rochester, Minnesota)
egarding outcome of MR surgery.
tudy subjects. Inclusion criteria were as follows: 1) mitral
urgery (repair or replacement) at our institution between
anuary 1, 1980, and December 31, 1995; and 2) indicated
or MR pure (no stenosis) and isolated (no aortic or
ricuspid disease more than trivial). Exclusion criteria were
resence of mitral stenosis, congenital or pericardial disease,
revious mitral valve surgery, and previous or simultaneous
ortic or tricuspid valve replacement (tricuspid repair was
ot an exclusion criteria). Patients with associated CABG
ere not excluded.
linical practice and definitions. Baseline characteristics
nd comorbidity were recorded as noted by a patient’s
ersonal physician at our institution. pre-operative echocar-
iographic data were prospectively measured for patient
valuation and collected for this study by electronic down-
oad without alteration. Mitral repair was guided by the
urgeon’s assessment of lesions (21), and replacement was
erformed if repair was impossible. Choice of mechanical or
iological prosthesis was based on discussion between pa-
ient and surgeon. Preservation of posterior leaflet chordae
as systematic, and specific surgical details (anterior leaflet
hordae, foramen ovale, atrial closure) varied according to
urgeon’s decisions. Post-operatively, the use of heparin
ollowed by warfarin sodium was usual, but the intensity and
uration of anticoagulation were determined by personal
hysicians according to anticoagulation guidelines. Treat-
ent with warfarin sodium was recorded if administered
3 months post-operatively. Events were determined by
eview of medical records, hospital notes, questionnaires,
nd telephone calls to patients, families, and physicians.
omplete follow-up was available for 1,321 (98.2%) pa-
Abbreviations
and Acronyms
AF  atrial fibrillation
CABG  coronary artery
bypass grafting
ICH  intracranial
hemorrhage
IS  ischemic stroke
MR  mitral regurgitation
MRep  mitral valve repair
MVR  mitral valve
replacement
RR  risk ratio
TE  thromboembolic
event
TIA  transient ischemic
attackients. Neurological diagnoses were made by neurologists wntegrating all information available regarding neurological
ymptoms, examination at event, and during follow-up
isits and neurovascular imaging. All neurological diagnoses
ere based on validated definitions (18,22–24). Ischemic
troke was persistent (24 h) focal neurological deficit
ttributed to altered circulation of cerebral hemispheres,
rain stem, or cerebellum. Computed tomography or mag-
etic resonance during an acute episode were not indispens-
ble to neurological diagnosis (obtained in 125 of 201
atients, 62% with IS or transient ischemic attack [TIA])
18,24). A TIA was a focal neurologic event of complete
nd rapid resolution (24 h) related to altered brain
irculation (23,24). Peripheral embolic event was defined by
perative, autopsy, or clinical documentation of embolism
ausing peripheral (noncerebral) arterial obstruction (24).
leeding event was internal or external bleeding causing
eath, hospitalization, or permanent injury or requiring
ransfusion (24). Intracranial hemorrhage (ICH) was diag-
osed with the use of imaging or autopsy. Atrial fibrillation
as diagnosed with the use of electrocardiogram.
tatistical analysis. Baseline characteristics are presented
s mean SD for continuous variables. Group comparisons
sed a standard t test or chi-square test as appropriate.
irst-event rates were estimated with the Kaplan-Meier
ethod censoring after the first event or at end of follow-
p, and multiple events were accounted for by yearly
inearized rates, all expressed in percent per year  SE (24).
bsolute hazards of embolisms were examined and periods
f high, medium, and low risk were defined based on
nflections of the time-hazard curves. First event rates were
ompared between groups using the 2-sample log-rank test
nd with expected rates in an Olmsted County population
matching for gender, age, and rhythm from the Rochester,
innesota Stroke Registry) by using the 1-sample log-rank
est. Logistic regression was used to predict first events at
pecific intervals (30 and 180 days) after surgery. Cox
roportional hazards modeling was used to define long-term
rst events’ predictors. Variables with p 0.10 by univariate
nalysis were candidate predictors in multivariate models,
nd p  0.05 was significant.
esults
aseline characteristics. During the study, 1,344 patients
ad surgery for MR, MRep in 897 (67%), mechanical mitral
alve replacement (MVRm) in 231 (17%), and biological
itral valve replacement (MVRb) in 216 patients (16%).
eoperation was performed in 133 patients during follow-
p. Mitral regurgitation etiology was myxomatous valve in
56, ischemia in 261, endocarditis in 76, rheumatic fever in
6, and miscellaneous in 65 patients. Bioprostheses were
arpentier-Edwards (Edwards LLC, Irvine, California) in
59, Ionescu-Shiley in 43, Hancock in 11, and Medtronic
ntact (Medtronic Inc., Minneapolis, Minnesota) in 3
atients. Mechanical prostheses were Starr-Edwards (Ed-
ards LLC) in 143, St. Jude (St. Jude Corp., St. Paul,
M
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March 25, 2008:1203–11 Stroke After Mitral Surgeryinnesota) in 59, Bjork-Shiley in 27, and Hall-Medtronic
Medtronic Inc.) in 2 patients. We performed CABG in
07 patients. The pre-operative characteristics summarized
n Table 1 show differences between MRep, MVRm, and
VRb, particularly for age. Atrial fibrillation (AF) was
resent pre-operatively in 544 patients (Table 1), and 168
atients developed AF during follow-up. Warfarin sodium
reatment was prescribed after surgery for 51% of patients
95% with MVRm who survived to receive permanent
nticoagulation). Patients with TE are also listed in Table 1
verall and by surgical procedure.
S after MR surgery. We found that IS occurred in 130
atients (most frequent TE, Table 1) with full resolution of
S manifestations in only 23 (18%). The incidence of IS was
.9  0.4% (30-day), 2.7  0.5% (180-day), and 8.1 
.8% (5-year follow-up) in excess of expected rate for this
opulation (p  0.0001). Linearized rate of first IS was
.5  0.1 per 100 patient-years (Table 2), and when
ccounting for 29 recurrent IS, was 1.75  0.1 per 100
atient-years. However, marked rate changes were noted over
ime. Table 2 shows contrasting high early linearized rates;
hile most events occurred later, there were higher long-term
S rates after MVRm than after other corrections (p 0.0001)
Fig. 1). Within the first 30 days, IS incidence was greater
fter MVRb (4.6  1.5%) than MRep (1.5  0.4%) or
aseline, Operative, and Post-Operative Characteristics
Table 1 Baseline, Operative, and Post-Operative Characteristic
Population Variables
Overall
(n  1,344)
Pre-operative clinical characteristics
Age, yrs 65 12
Male gender, % 61
Hypertension, % 36
Diabetes, % 10
Creatinine, mg/dl 1.4 0.6
Organic MR, % 81
AF, % 41
NYHA functional class III to IV, % 57
Pre-operative echocardiographic characteristics
EF, % 58 13
LVD, mm 61 9
LVS, mm 39 12
LAD, mm 54 10
Operative and post-operative characteristics
Bypass time 98 48
CABG, % 38
Warfarin sodium therapy, % 51
Patients with thromboembolic complications, n (%)*
Ischemic stroke 130 (10%)
TIA 81 (6%)
Peripheral TE 21 (1.6%)
Any TE 212 (16%)
n indicates the number of patients with the complication, and the percentages are calculated as
umber of patients in the series or group.
AF  atrial fibrillation; CABG  coronary artery bypass graft; EF  ejection fraction; LAD  le
iameter; MR  mitral regurgitation; MRep  mitral valve repair; MVRb  mitral valve replaceme
hromboembolic event; TIA  transient ischemic attack.VRm (1.3  0.8%, p  0.0001). Up to 180 days, MRep (howed the lowest IS incidence versus MVRm and MVRb.
fter 180 days, IS rates were lowest after MRep and MVRb
ersus MVRm (Table 2). There was no significant differ-
nce in stroke rates between the 30- to 90-day follow-up
nd the 90- to 180-day follow-up.
A comparison of IS observed versus expected in Olmsted
ounty population with similar characteristics, particularly
ge, is presented in Table 3. For all patients and all times,
bserved-to-expected IS risk ratio (RR) is 2.1 (doubling of
pontaneous risk), but with marked time and procedure
eterogeneity. Indeed, excess risk versus expected is very
igh at 30 days (RR 41, similar for all procedures) but
eclines to 1.7 thereafter. The pattern of early high risk
eclining long term is similar with MRep and MVRb, with
imilar IS risk ratios to expected (1.6 vs. 1.7). For MRep
nd MVRb, 180 days IS risk returns to that of general
opulation. However, for MRep, IS risk remains elevated at
30 days, up to 180 days. With MVRm excess IS risk is
igh, that is, 4 to 10 times normal throughout follow-up.
redictors of IS. For IS 30 days, univariate predictors
ere age, female gender, intra-aortic balloon pump, coro-
ary disease, hypertension, and MVRb (Table 4). Only
emale gender was weakly associated with early IS indepen-
ently of age (p  0.047). For IS at 30 days to 180 days,
ndependent predictors were age, hypertension, and MVRm
MRep
(n  897)
MVRm
(n  231)
MVRb
(n  216) p Value
65 12 60 11 70 11 0.0001
64 62 48 0.0001
37 29 39 0.03
8 11 13 0.07
1.4 0.7 1.3 0.6 1.3 0.4 0.92
83 80 69 0.0001
37 51 44 0.0006
48 69 78 0.0001
59 12 56 14 56 14 0.02
61 9 61 9 61 9 0.91
39 13 39 10 39 10 0.97
54 9 54 10 54 11 0.85
90 47 110 49 118 50 0.0001
38 33 43 0.13
41 95 44 0.0001
65 (7%) 44 (19%) 21 (10%)
50 (6%) 21 (9%) 10 (5%)
11 (1.2%) 6 (2.6%) 4 (1.9%)
114 (13%) 64 (28%) 34 (16%)
io of n with the listed thromboembolic complications during follow-up for each group by the total
diameter; LVD  left ventricular diameter; LVS  left ventricular end-diastolic and end-systolic
gical; MVRm  mitral valve replacement mechanical; NYHA  New York Heart Association; TE s
the rat
ft atrialTable 4). Beyond 6 months, univariate IS predictors were
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Stroke After Mitral Surgery March 25, 2008:1203–11ge, MVRm, AF at surgery or before the event, and left
trial dimension 50 mm. Independent IS predictors at
180 days were age and MVRm, whereas MRep was
ndependently predictive of less-frequent IS (Table 4) (RR
.5, 95% confidence interval [CI] 0.3 to 0.8). Although AF
as not predictive overall of IS (p 0.10), after exclusion of
atients with MVRm, AF was, independently of age,
ssociated with a greater stroke rate (p 0.05; RR 1.4, 95%
I 1.01 to 3.8). A history of pre-operative stroke was not
nivariate (p  0.66) or adjusted (p  0.69) independently
redictive of post-operative IS.
ncidence of ischemic stroke or TIA. Transient ischemic
ttack occurred in 81 patients, followed by IS in 10 and
Incidence of Ischemic Stroke Event After MRSurg ry Overall and by Surgical Procedure and P
Table 2 Incidence of Ischemic Stroke EventSurgery Overall and by Surgical Pro
Group Entire <30 Days
Overall Events: 130 Events: 25
5 yrs: 8.1 0.8% 30 days: 1.9
10 yrs: 12.9 1.2% 23.9 4.8 %
1.5 0.1 %PY
MRep Events: 65 Events: 13
5 yrs: 6.1 0.9% 30 days: 1.5
10 yrs: 9.9 1.3% 18.3 5 %PY
1.15 0.1 %PY
MVRm Events: 44 Events: 3
5 yrs: 16.1 2.7% 30 days: 1.3
10 yrs: 23.3 3.5 16.6 9.6 %
2.7 0.4 %PY
MVRb Events: 21 Events: 9
5 yrs: 8.0 2.1% 30 days: 4.6
10 yrs: 12.2 2.9% 60 20 %PY
1.65 0.4 %PY
In each cell, “events” indicates the number of ischemic strokes for the
time at which they are estimated and  SE of the estimate; the last l
PO  post-operatively; %PY  per 100 patient-years; other abbrevi
Figure 1 Incidence of First Ischemic
Stroke After Surgery for Mitral Regurgitation
The numbers with each curve indicate the 5-year estimated rate of ischemic
stroke  SE. MRep  mitral valve repair; MVRb  mitral valve replacement
biological; MVRm  mitral valve replacement mechanical.isolated in 71, and IS/TIA occurred in 201 patients (2.6 
.5% at 30 days, 13.4 1% and 20 1% at 5 and 10 years).
e found that IS/TIA was similar in MRep, MVRm, and
VRb at 30 days (2.4  0.5%, 1.8  0.9%, 4.6  1.5%,
 0.10) and 180 days (3.9 0.6%, 4.1 1%, 6.3 1.7%,
 0.10). At 5 years, IS/TIA was lowest in MRep, 10.9 
.1% (2.0  0.2% patient-years), which was not different
rom MVRb, which was 13.2  2.6% (2.6  0.5% patient-
ears), but lower than MVRm, which was 23.4  3.1%
p  0.0001, 4.1  0.5% patient-years). Compared with
xpected IS/TIA in general population, at 30 days, excess
isk was consistent (overall RR 43) regardless of procedure
Table 5). Beyond 30 days, risk remained significantly high
ersus expected, and although it decreased markedly over
ime in all groups, it remained considerable in MVRm
eyond 180 days (RR 4.9) (Table 5).
CH and total strokes (IS/ICH). Ten patients experi-
nced ICH: 1 in MRep, 5 in MVRm, and 4 in MVRb. In
ddition, 1 patient had subarachnoid hemorrhage. Com-
ared with population-expected ICH, MRep had low rela-
ive risk (0.17, 95% CI 0.0 to 0.97, p  0.04) and MVRm
ad high relative risk (3.8, 95% CI 1.2 to 8.8, p  0.003),
hereas MVRb had notable relative risk (2.2, 95% CI 0.6 to
.7) but did not reach statistical significance (p 0.12). For
S or ICH stroke (140 patients), comparison with
opulation-expected rates shows high relative risk with
VRm (5.2, 95% CI 3.8 to 6.9, p 0.0001) both30 days
39, 8.1 to 115, p  0.0001) and after 30 days (4.9, 3.6 to
.5). For MRep and MVRb, IS/ICH risk became similar to
xpected after 30 days.
ll embolic events (IS, TIA, peripheral, and mesenteric
mbolism). Post-operatively, 212 patients experienced TE
perative Phase
r MR
re and Post-Operative Phase
ollow-Up
30–180 Days PO >180 Days PO
Events: 10 Events: 95
180 days: 2.7 0.4% 1.2 0.1 %PY
2.02 0.6 %PY
Events: 5 Events: 47
180 days: 2.1 0.5% 0.9 0.1 %PY
1.5 0.6 %PY
Events: 4 Events: 37
180 days: 3.2 1.2% 2.5 0.4 %PY
4.7 2.3 %PY
Events: 1 Events: 11
180 days: 5.2 1.6% 0.9 0.3 %PY
1.5 1.5 %PY
and procedure. Incidences of ischemic strokes are indicated with the
cates the yearly linearized rate (SE) of ischemic strokes.
s in Table 1.ost-O
Afte
cedu
F
PO
 0.4%
PY
 0.4%
 0.8%
PY
 1.5%
periodrrespective of location (Table 6). MRep had the lowest
i
p
[
f
0
I
i
a
5
t
1
1
p
(
w
g
C
0
a
r
p
D
T
o
s
p
o
c
a
s
l
c
e
r
t
M
n
d
s
i
E
e
b
l
I
l
r
s
d
ates of
I
O
o
1207JACC Vol. 51, No. 12, 2008 Russo et al.
March 25, 2008:1203–11 Stroke After Mitral Surgeryncidence at 11.6  1.1% after 5 years (2.1  0.2%
atient-years), which is lower than MVRm (23.8  3.1%
4.3  0.5% patient years, p  0.001]) but not different
rom MVRb (14.9  2.8% [2.8  0.5% patient-years, p 
.10]), a difference sustained at 10 years (Fig. 2).
ncidence and predictors of bleeding. Bleeding occurred
n 136 patients (58 MRep, 39 MVRm, and 39 MVRb), 51
t 30 days (3.9  0.5%). Excluding these early bleedings,
- and 10-year rates were 5  1% and 10  1%, respec-
ively. Lower 10-year rates were observed with MRep (7 
%, 0.7  0.1% patient-years) versus MVRb (14  4%,
.7% patient-years) and MVRm (16  3%, 3.4  0.5%
atient-years). Early (30-day) bleeding was only age-related
p  0.007). Long-term bleeding independently increased
ith age (RR 1.14, 95% CI 1.02 to 1.27 per 5 years), male
ender (1.65, 95% CI 1.04 to 2.7), and MVRm (2.5, 95%
I 1.5 to 3.9), and decreased with MRep (0.39, 95% CI
.25 to 0.61). Patients justifying intention to treat by
nticoagulation (AF or MVRm) incurred a higher bleeding
First Ischemic Stroke Risk After MR Surgery ExRisk Ratio to Expected First Ischemic Stroke R
Table 3 First Ischemic Stroke Risk After MRRisk Ratio to Expected First Ischem
Group Entire <30 Days PO
Overall series
Risk ratio 2.1 41
95% CI 1.8–2.5 26–60
p value* 0.001 0.001
MRep
Risk ratio 1.6 31
95% CI 1.3–2.1 16–53
p value* 0.001 0.001
MVRm
Risk ratio 5.1 43
95% CI 3.7–6.9 9–126
p value* 0.001 0.001
MVRb
Risk ratio 1.7 72
95% CI 1.1–2.6 33–137
p value* 0.01 0.001
*p value applies to the comparison between observed and expected r
CI  confidence interval; other abbreviations as in Table 1.
ndependent Predictors of Firstschemic Strok Af e MR Surgery
Table 4 Independent Predictors of FirstIschemic Stroke After MR Surgery
Predictors
<30 Days PO
OR, 95% CI
p Value
30–180 Days PO
OR, 95% CI
>180 Days PO
RR, 95% CI
Female gender 2.3, 1.01–5.4
0.047
Hypertension 4.3, 1.2–20
MVRm 6.0, 1.4–25 3.0, 1.9–4.65
Age (per 5 yrs) 1.4, 1.0–2.3 1.1, 1.03–1.3
MRep 0.5, 0.3–0.8c
R odds ratio (by logistic models); RR risk ratio (by Cox proportional hazards survival models);
ther abbreviations as in Tables 1 and 2.ate independently of age (1.52, 95% CI 1.08 to 2.15,
 0.02).
iscussion
he present study, which analyzes a large cohort of patients
perated for MR for time dependence of TE events after
urgery and compares IS rates to the general population,
rovides a unique view of TE events after MR surgery. Our
bservations are both concerning and encouraging. Con-
erns stem from excess risk of IS and of IS-TIA. Encour-
ging is the decline of TE events over time post-operatively,
o that in MRep or MVRb, IS rates are not different in the
ong term from the general population. Thus, MRep, which
ompared with MVR results in the restoration of life
xpectancy, also has the advantage of imposing no excess IS
isk after the sixth post-operative month and is confirmed as
he preferred surgical correction of MR. Conversely,
VRm is associated, beyond the excess mortality previously
oted, with sustained risk of IS and bleeding and is the least
esirable correction of MR. Beyond these broad conclu-
ions, it is important to examine detailed TE risk and how
t can be minimized.
arly TEs. Previous research focused on thromboembolic
vents early after cardiac surgery, mostly after coronary
ypass surgery (1,4–7). Early TE events directly causally
inked to surgery are important. In our series, rates of IS or
S/TIA early after surgery (30 days) of 1.9% and 2.6% are
ower than reported after coronary bypass (1,4,7). These
ates are also lower than neurologic events after mitral
urgery (3,11), particularly because of a strict neurological
efinition of IS or TIA (18), but are high enough to justify
ed asin the Population
gery Expressed as
troke Rates in the Population
Follow-Up
Days PO 30–180 Days PO >180 Days PO
.7 2.9 1.6
.4–2.1 1.4–5.3 1.3–1.9
.3 2.1 1.2
7–1.7 0.7–4.8 0.9–1.6
.8 10.4 4.3
.4–6.5 2.8–27 3–5.9
.98 1.5 0.9
.5–1.7 0.1–8.5 0.5–1.6
first ischemic stroke.pressat
Sur
ic S
>30
1
1
1
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4
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0areful attention. Macroembolization is now rare, involving
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Stroke After Mitral Surgery March 25, 2008:1203–11hrombotic, fat, or gaseous emboli from extracorporeal cir-
ulation or aortic atherosclerosis (25–27). The risk of TE is
ot just procedural and remains high within 30 days
approximately 40 the risk of spontaneous IS). Prosthetic
aterials activate platelets with sustained platelet deposition
28) and clot formation. This observation justifies preven-
ion of thrombus formation after MR surgery, irrespective
f procedure (13,29). Higher early TE and IS risk in women
s poorly explained, but coherent observations (9,30) under-
core the need for prospective mechanistic studies address-
ng this excess risk.
ong-term thromboembolic and hemorrhagic compli-
ations. A clear result involves late complications of
VRm, which was unclear in previous studies. For
Risk of the Combined End Point First IS-TIA AfteSurgery Compared With Expected First IS-TI R
Table 5 Risk of the Combined End Point FirSurgery Compared With Expected F
Group Entire <30 Days PO
Overall series
Risk ratio 2.7 43
95% CI 2.4–3.2 30–60
p value* 0.001 0.001
MRep
Risk ratio 2.2 39
95% CI 1.8–2.7 24–59
p value* 0.001 0.001
MVRm
Risk ratio 5.8 43
95% CI 4.4–7.4 11.6–109
p value* 0.001 0.001
MVRb
Risk ratio 2.2 57
95% CI 1.5–3.1 26–106
p value* 0.001 0.001
*p values applies to the comparison between observed and expected
IS-TIA  ischemic stroke-transient ischemic attack; other abbreviat
Incidence of Any Thromboembolic Event AfterMR Surg ry Overall and by Surg al Procedure a
Table 6 Incidence of Any Thromboembolic EMR Surgery Overall and by Surgical
Group Entire <30 Days PO
Overall 5 yrs: 14.2 1% 30 days: 2.9 0.5%
10 yrs: 20.7 1.4% 38.6 5.8 %PY
2.6 0.2 %PY
MRep 5 yrs: 11.6 1.1% 30 days: 2.5 0.5%
10 yrs: 17.2 1.7% 31 6.6 %PY
2.1 0.2 %PY
MVRm 5 yrs: 23.8 3.1% 30 days: 1.8 0.9%
10 yrs: 33.1 3.8% 22.2 11.1 %PY
4.3 0.5 %PY
MVRb 5 yrs: 14.9 2.8% 30 days: 5.7 1.6%
10 yrs: 20.8 3.5% 73.5 22.15 %PY
2.8 0.5 %PY
In each cell, incidences of embolic events are indicated with the time a
yearly linearized rate (SE) of ischemic strokes.
Abbreviations as in Table 1.VRm, a clinical trial did not suggest excess stroke rate
14) but was contradicted by clinical practice studies
howing high rates of TE (2,9,31,32). Our large long-
erm study emphasizes greater TE and IS rates with
VRm than MVRb (9) or MRep. Despite declining
ates of IS over time, excess risk with MVRm is evident
6 months. Risk estimation is difficult due to younger
ge with MVRm versus MVRb, but comparison to the
ge-expected rate of IS or IS/TIA shows that MVRm
ultiplies long-term risk by 4 to 5. Also, in multivariate
nalysis, IS risk with MVRm is 3 greater versus MVRb.
VRm requires anticoagulation with a notable bleeding
ate, 3% yearly, which is 2.5 higher versus MVRb.
his combined inherent excess risk should be a renewed
in the Population
TIA After MR
S-TIA Rates in the Population
Follow-Up
Days PO 30–180 Days PO >180 Days PO
2.3 4.7 2.0
5–2.7 2.9–7.2 1.7–2.4
1.8 4.2 1.6
5–2.2 2.2–7.2 1.2–1.9
5.4 9.6 4.9
1–7.0 3.1–22 3.7–6.5
1.6 3.7 1.4
0–2.4 1.0–10.7 0.8–2.1
f first IS-TIA.
 in Tables 1, 2, and 3.
O Phase
After
edure and PO Phase
low-Up
30–180 Days PO >180 Days PO
180 days: 4.7 0.6% 2 0.1 %PY
4.7 1 %PY
180 days: 4.2 0.7% 1.6 0.2 %PY
4.2 1.1 %PY
180 days: 4.6 1.4% 3.9 0.5 %PY
7.1 2.9 %PY
180 days: 7.4 1.9% 1.8 0.4 %PY
4.5 2.6 %PY
they are estimated,1 SE of the estimate. The last line indicates ther MRates
st IS-
irst I
>30
1.9
1.
4.
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March 25, 2008:1203–11 Stroke After Mitral Surgeryncentive to make all efforts to avoid MVRm for MR
orrection.
For MVRb and MRep, we also observed a marked risk
ecline 30 days. MRep was associated with the lowest
bsolute rate of TE, IS, and IS/TIA. This advantage of
Rep was controversial (19,33,34), and age differences
equire comparison with expected rates. A remarkable result
s that IS risk (the most frequent and serious TE compli-
ation) is similar 180 days in MVRb and MRep and not
ignificantly elevated compared to the general population.
hus, MRep results in long-term restoration not only of life
xpectancy (35,36) but also of IS risk. MRep is also
emarkable by providing the lowest bleeding risk and is
nique in combining long-term morbidity to mortality
enefit.
linical and preventive implications. Our study shows
hat, after MR surgery, immediate IS risk is close to 2%
verall and slightly 1% for valve repair. This risk should,
n our opinion, not discourage early surgery in asymptom-
tic patients, recently endorsed by guidelines (15), but
hould be made clear to patients considering MR surgery.
or procedure choice, our data reinforce MRep preference
or surgical correction of MR. The previously demonstrated
Rep survival benefit (19) and lowest risk of embolism and
emorrhage concur in supporting this approach. The return
f IS risk to that in the general population 6 months after
Rep is particulary important in asymptomatic patients in
hom a low rate of post-operative complications is essential
o the operative decision. If repair is not possible, MVRb,
ith lower TE and hemorrhagic risk than MVRm, should
e carefully considered.
Early IS risk is only transient, but strategies should be
eveloped to lower it. A similar risk with MVRm versus
Rep or MVRb may reflect more careful attention at
nticoagulation. Effective anticoagulation assessment re-
Figure 2 Incidence of Any First TEs After Surgery for MR
The numbers with each curve indicate the 5- and 10-year estimated rate of
TEs  SE. MR  mitral regurgitation; TE  thromboembolic event; other abbre-
viations as in Figure 1.uires prospective evaluation, but our data clearly emphasize che need for effective anticoagulation. Other potential TE
eterminants and therapeutic interventions have been pre-
iously discussed. Antithrombotic medication, such as aspi-
in, have risks but also benefits (37) that should be evalu-
ted. Atrial fibrillation is frequent after surgery and may
ontribute to TE (38). The association of diagnosed atrial
brillation with IS or IS/TIA was weak overall but, exclud-
ng MVRm (with high TE risk irrespective of rhythm), AF
redicted risk of IS, TE (relative risk 1.5, 95% CI 1.1 to 2.1,
 0.002), and embolism or bleeding (1.4, 95% CI 1.1 to
.7, p  0.035). Although surgical AF prevention (39) and
eft atrial appendage closure (40) deserve further investiga-
ion, these findings suggest that AF is not benign in MR,
ustifying surgery after AF but also suggesting that early
urgery in sinus rhythm may provide best outcome.
Beyond the initial high-risk 30-day phase, exact bound-
ries of intermediate risk are difficult to define. A compar-
son to expected IS risk provides new insights (29). Slow
ealing of mitral repair, which is up to 12 weeks (41) for
omplete endothelial restoration (42), may be linked to 30
o 180 days’ TE risk. Whether prolonged anticoagulation
fter MRep would prevent IS and TIA during this inter-
ediate phase is conjectural but should be considered
ecause such finite anticoagulation represents modest bleed-
ng risks. Chronically, IS risk of MRep is low and anti-
hrombotic treatment should be individualized (37). In
lder patients with MVRb and faster endothelial restoration
43,44), no excess embolic risk is noted 30 days and
rolonged anticoagulation is of dubious benefit (45).
High long-term TE-risk after MVRm despite anticoag-
lation is a concern. Frequent monitoring of anticoagulation
as linked to low TE rates (46), and home self-monitoring,
hich now is widely applicable, appears beneficial in pilot
rials (47) and is attractive in view of sustained high embolic
nd hemorrhagic risk in MVRm.
tudy limitations. Different baseline characteristics be-
ween surgical procedures, particularly age, are expected.
eyond comparing absolute TE rates, adjusting for age in
ultivariate analysis and comparison to age-expected IS or
S/TIA risk accounted for these differences. The analysis of
id- and long-term post-operative phases (30 to 180 days
nd 180 days) carries the potential for bias because the
ensoring of early events (left-truncation) is justified by
hanging events hazards over time. Thus, interpretation of
artial rates should be prudent and emphasizes the impor-
ance of comparison to expected risk (48). With change in
E hazard over time, quality criteria for anticoagulation are
mperfectly defined. Thus, obtaining measures of compli-
nce, regularity, and efficacy were not possible in our study.
e could not measure how specific anticoagulation char-
cteristics may be linked to embolic and hemorrhagic risks,
nd thus comprehensive community studies and clinical
rials are necessary. However, by demonstrating excess risk
ncurred by patients undergoing MR surgery, candidates for
linical trials can be better defined. Conversely, long-term,
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Stroke After Mitral Surgery March 25, 2008:1203–11Rep and MVRb are not linked to excess IS risk, a
eassuring observation.
onclusions
his large study of MR surgery provides observations
ausing both concern and encouragment regarding post-
perative TE events. Indeed, MR surgery is followed, versus
he general population, by excess IS risk and IS/TIA risk. It
s also concerning that, throughout, follow-up patients with
VRm incur a high risk of TE or bleeding. However,
ncouraging are the brisk decrease in TE rate after the early
ost-operative phase and the fact that, with MRep or
VRb, long-term IS rates are similar to the general
opulation. Thus, MRep provides, in addition to its low
ortality, the lowest morbidity and is confirmed as the
referred correction of MR. Conversely, MVRm shows
ustained risk of IS and bleeding and is least desirable for
R correction. To support guideline recommendation of
arly MR surgery in asymptomatic patients, MRep perfor-
ance is an essential condition, and clinical trials should be
esigned to minimize the risk of stroke after surgery.
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